Interferences in free thyroxine concentration using the Roche analytical platform: improvement of the third generation?

Ruth, Isabelle; Mathieu, Erin; Burniat, Agnès; Fage, David; Cotton, Frédéric; Wolff, Fleur

doi:10.1515/cclm-2019-0525

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typical thyroid function tests (TFTs) usually evaluate thyrotropin (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) levels [1]. Anti-streptavidin antibodies are causal determinants of analytical interference during TFTs [2,3], and numerous reports have detailed such interference, with anti-streptavidin antibodies attracting attention [1,[4][5][6][7]. We conducted a straightforward investigation of interference due to antistreptavidin antibodies during TFTs.…”

Section: Introductionmentioning

confidence: 99%

Falsely diagnosed thyrotoxicosis caused by anti-streptavidin antibodies and pre-wash procedures

et al. 2021

View full text Add to dashboard Cite

Background Anti-streptavidin antibodies are causal determinants of analytical interference during Thyroid function tests, and numerous reports have detailed such interference, with anti-streptavidin antibodies attracting attention. Case presentation We conducted a straightforward investigation of interference due to anti-streptavidin antibodies, with a case of a 60-year-old Japanese man who consulted our department for inconsistencies between his clinical course and Thyroid function tests. Experiments were conducted using Cobas8000 e602, which employs assay procedures with pre-wash to evaluate FT4 and FT3 levels. Conclusions To our knowledge, this is the first published report to clearly investigate such interferences using a combination of polyethylene glycol precipitation, heterophilic blocking tube precipitation, streptavidin-coated magnetic particle precipitation, and different instruments with or without pre-wash. Clinicians should consider that interferences caused by anti-streptavidin antibodies could lead to a misdiagnosis of thyrotoxicosis. Moreover, discussions between laboratory specialists, clinicians, and manufacturers are required to identify interferences and avoid unnecessary examinations and inappropriate treatment.

show abstract